Ascentage Pharma announced that for the second consecutive year, it has released updated data of APG-2449, a novel FAK/ALK/ROS1 tyrosine kinase inhibitor developed by Ascentage Pharma, in patients with non-small cell lung cancer, in a Poster Discussion session at the 59th American Society of Clinical Oncology Annual Meeting.
